HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial - Heather A. Prentice; Philip K. Ehrenberg; Karen M. Baldwin; Aviva Geretz; Charla Andrews; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; Robert J. O’Connell; Merlin L. Robb; Jerome H. Kim; et al. (Immunogenetics, 2014)